Top Markets
#1 GoPlus Security GoPlus Security +40.89%
#2 Tutorial Tutorial +30.33%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.15%
#4 SkyAI SkyAI +18.50%
#5 Status Status +15.36%
#6 Pons Pons +14.51%
#7 Verus Coin Verus Coin +13.17%
#8 Talus Network Talus Network +10.97%
#9 Ontology Gas Ontology Gas +9.49%
#10 DMT-NAT DMT-NAT +9.31%
Coin of the day
GoPlus Security GoPlus Security
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Incannex Healthcare Limited Incannex Healthcare Limited

Incannex Healthcare Limited

IHL
Rang in Aktien #33840
Established in Melbourne, Australia, in 2001, Incannex Healthcare Limited,... Established in Melbourne, Australia, in 2001, Incannex Healthcare Limited, which operated as Impression Healthcare Limited until its rebranding in June 2020, is dedicated to the research, development, and commercialization of pharmaceutical products and therapies derived from medicinal cannabinoids and psychedelics. Its offerings include a trio of ultrapure cannabinoid compounds: APIRx-1801 (tetrahydrocannabinol), APIRx-1802 (CBD), and APIRx-1803 (cannabigerol). The company's clinical pipeline features IHL-42X, which has concluded Phase IIa trials for obstructive sleep apnea, and Psi-GAD, currently in Phase IIa development for generalized anxiety disorder. Other compounds having successfully advanced through Phase IIa clinical trials include CanChew Plus for irritable bowel syndrome, APIRx-1601 for vitiligo, APIRx-1602 for psoriasis, and APIRx-1603 for atopic dermatitis. Additionally, MedChew Dronabinol has completed Phase Ia trials for chemotherapy-induced nausea and vomiting. Its pre-clinical portfolio is extensive, including IHL-675A, which has completed studies for inflammatory lung disease, rheumatoid arthritis, and inflammatory bowel disease, alongside IHL-216A for traumatic brain injury/concussion. A broad array of further candidates are actively undergoing pre-clinical investigation, such as MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpetic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for Crohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for cannabis addiction, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, and APIRx-1702 for dry eye syndrome.
Aktienkurs
$0.0270762
Zuletzt synchronisiert: 2023-11-30
Marktkapitalisierung
$6.78M
Veränderung (1 Tag)
-0.66%
Veränderung (1 Jahr)
0.00%
Land
AU
Handel Incannex Healthcare Limited (IHL)

Kategorie

Healthcare
Gewinn für Incannex Healthcare Limited (IHL)
Gewinn im 2026 TTM: 0
Laut den aktuellen Finanzberichten von Incannex Healthcare Limited betragen die aktuellen Gewinne des Unternehmens 0. Im Jahr 2026 erzielte das Unternehmen einen Gewinn von 0, gleich wie dem Gewinn im Jahr 2026, der 0 betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Incannex Healthcare Limited von 2026 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
Nicht genügend Daten für die angegebenen Daten.
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
- -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
- -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
- -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
- -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
$1.76B -
IN